Search Results

You are looking at 1 - 10 of 80 items for :

  • "EGFR inhibitor" x
  • All content x
Clear All
Full access

Emil Lou, Donna D'Souza, and Andrew C. Nelson

mutations do not benefit from treatment with epidermal growth factor receptor (EGFR) inhibitors. 4 During this time, there have been investigations examining whether this is broadly and universally true across all forms of KRAS mutations, or whether any

Full access

Barbara Burtness, Milan Anadkat, Surendra Basti, Miranda Hughes, Mario E. Lacouture, Joan S. McClure, Patricia L. Myskowski, Jennifer Paul, Clifford S. Perlis, Leonard Saltz, and Sharon Spencer

with anti-epidermal growth factor receptor therapy: survey results . Oncology 2007 ; 72 : 152 – 159 . 28 Wagner LI Lacouture ME . Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective. Impact on

Full access

Barbara Burtness

assortment of adverse skin effects are associated with the use of epidermal growth factor receptor (EGFR) inhibitors such as cetuximab and erlotinib. Although papulopustular rash may be the most commonly observed side effect of these targeted agents, non

Full access

Presenter: Dustin A. Deming

. Historically, targeting BRAF became an exciting concept based on successes seen in melanoma. Although response rates to single-agent BRAF inhibitors in CRC are low, results of BRAF in combination with MEK or EGFR inhibitors have been more encouraging. “Not

Full access

Amy Zhou, Manik Amin, Kathryn J. Fowler, Elizabeth M. Brunt, Jesse Keller, and Benjamin Tan

combination of an epidermal growth factor receptor (EGFR) inhibitor and a vascular endothelial growth factor (VEGF) inhibitor. Case Presentation During a workup for chest pain in a 77-year-old Caucasian woman, a 3-cm liver lesion was found incidentally

Full access

Kristin K. Deeb, Jakub P. Sram, Hanlin Gao, and Marwan G. Fakih

constantly increasing number of molecular mutations. NGS provided sensitivity superior to Sanger sequencing and pyrosequencing in detecting EGFR and KRAS mutations in lung cancer specimens and clinical response to EGFR inhibitor. 42 Challenges remain for

Full access

Paul F. Engstrom

Full access

Tanios Bekaii-Saab

-positive mCRC. Despite these preliminary findings, there was very little uptake for incorporating an all- RAS mutational analysis before using EGFR inhibitors in mCRC. Why the initial reluctance? In addition to the lack of available standardized testing to

Full access

Mario E. Lacouture

made several key points about skin rash produced by different cancer therapies: Most patients taking EGFR inhibitors develop an acneiform rash on the face, scalp, and upper body, often within the first 4 weeks. This is associated with pruritus

Full access

by the ORP. This feature highlights an NCCN study funded through the grant mechanism. A Phase II Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor–Naïve Advanced EGFR -Mutant Lung Cancer Principal Investigator: Pasi Janne, MD